Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › FP7

PEVNET · Persistent virus infection as a cause of pathogenic inflammation in type 1 diabetes - an innovative research program of biobanks and expertise

FP7Status: CLOSED1 January 201130 June 2016EU funding €5,999,687

Type 1 diabetes is caused by an inflammatory process which damage insulin-producing beta-cells in the pancreas. It is one of the most common chronic diseases and its incidence is rapidly increasing. Due to its complications it causes a significant medical and economic burden to European society. A causal association between enterovirus and type 1 diabetes has become more and more likely. The aim of the present research programme is to create a new research strategy aligned to a concerted scientific research effort and creation of a network of unique resources which makes it possible to achieve a significant breakthrough in this field. The main focus is in the detection of persistent enterovirus infection leading to inflammation and tissue damage in the pancreas and its role in mediating the inflammatory response that causes type 1 diabetes. The goal is to take the critical steps towards therapeutic translation of research findings by employing a novel research design and synergistic networks of excellence based on the combination of a multidisciplinary research strategy and availability of unique biobanks existing in Europe. This research programme will also create a completely new type of biobank which facilitates a wide range of new analyses of fresh tissues. The programme includes a strong translational component which facilitates the ongoing efforts to develop vaccines against diabetogenic enteroviruses and other targeted therapies. The program also has a wider impact on the entire field of research on pathogen-disease associations, since the same innovative research strategy can be applied to other diseases as well. Altogether, this research program will take full advantage of the excellent biobank networks and a long tradition in biomedical and clinical research in Europe and creates an exceptional opportunity to take the final steps towards proving causality in the enterovirus-diabetes association.

Consortium · 14 organisations

coordinator

TAMPEREEN YLIOPISTO

FI · €820,760

participant

LINKOPINGS UNIVERSITET

SE · €120,000

participant

THE UNIVERSITY OF EXETER

UK · €346,434

participant

HELSINGIN YLIOPISTO

FI · €362,400

participant

UNIVERSITA DEGLI STUDI DI SIENA

IT · €493,000

participant

THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE

UK · €260,011

participant

VACTECH OY

FI · €247,200

participant

CENTRE HOSPITALIER REGIONAL ET UNIVERSITAIRE DE LILLE

FR · €348,000

participant

UPPSALA UNIVERSITET

SE · €1,242,918

participant

DIAMYD THERAPEUTICS AB

SE · €133,200

participant

UNIVERSITETET I OSLO

NO · €459,000

participant

KAROLINSKA INSTITUTET

SE · €349,764

participant

TURUN YLIOPISTO

FI · €477,000

participant

KING'S COLLEGE LONDON

UK · €340,000

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.